Latest news with #PursueCare
Yahoo
23-04-2025
- Business
- Yahoo
Connecticut Innovations Invests $7.4 Million in Early-Stage Companies in Q3 FY25
Deals leveraged $74.9 million in outside capital in the third quarter of the fiscal year NEW HAVEN, Conn., April 23, 2025 /PRNewswire-PRWeb/ -- Connecticut Innovations (CI), Connecticut's strategic venture capital arm, today announced that it invested approximately $7.4 million in 19 companies and venture funds during the third quarter of its fiscal year, ending March 31, 2025. CI's investments leveraged $74.9 million in outside capital and generated $4.9 million in proceeds during the quarter. CI invested close to $5 million in the healthcare sector, and approximately $1.4 million in climate tech. The remaining $1 million was invested in consumer companies and venture funds. "Healthcare continues to be one of CI's largest areas of investment," said Matt Storeygard, senior managing director of investments. "This quarter, we grew our healthcare portfolio with the addition of PursueCare, a tech-enabled, digital health startup offering evidence-based treatment, counseling, psychiatry and medication-assisted treatment through its innovative telehealth platform." To date, CI has invested $34.8 million and leveraged $566.8 million in FY25. "Despite fluctuations in the market, CI is still finding investment opportunities, growing Connecticut's innovation ecosystem and helping our current portfolio scale," said Peter Longo, senior managing director of investments. "Our team will continue to prioritize the growth of our companies as we navigate the current economic climate." Throughout FY25, CI has had 134 angels invest $16 million in 33 qualified Connecticut businesses through the Angel Investor Tax Credit Program. Applications on CI's site for angel investors will reopen on Sunday, June 1, 2025, and new approvals will be made beginning on Tuesday, July 1, 2025. About Connecticut Innovations: Connecticut Innovations (CI) is Connecticut's strategic venture capital arm and is the leading source of financing and ongoing support for innovative, growing companies. By offering equity and debt investments, strategic guidance and introductions to valuable partners, we help promising businesses to thrive. For more information, please visit Media Contact Lauren Carmody, Connecticut Innovations, 860.258.7829, View original content to download multimedia: SOURCE Connecticut Innovations Sign in to access your portfolio
Yahoo
21-04-2025
- Health
- Yahoo
PursueCare to Spotlight Next-Gen Digital Therapeutics at the 56th American Society of Addiction Medicine (ASAM) Conference in Denver April 24-27
Celebrates ASAM Distinguished Fellow Honor for Dr. Jason Kirby DENVER, April 21, 2025--(BUSINESS WIRE)--PursueCare, a leading provider of virtual addiction treatment and specialized pharmacy services, is proud to announce its participation in the 56th Annual American Society of Addiction Medicine (ASAM) Conference in Denver, Colo., April 24-27, 2025. The event gathers top experts, clinicians, and innovators in addiction medicine to advance science, practice, and policy in the field. Honoring a Visionary in Addiction Medicine—Dr. Jason Kirby Named 2025 ASAM Distinguished Fellow PursueCare's Medical Director, Dr. Jason Kirby, DO, MBA, DFASAM, has been named a 2025 Distinguished Fellow of ASAM, one of the society's highest honors. This prestigious designation recognizes Dr. Kirby's enduring commitment to evidence-based, outcomes-driven care and his leadership in improving access to treatment for individuals with substance use disorder (SUD). "I began this journey nearly a decade ago with a mission to provide compassionate, science-backed care for people living with addiction. Being recognized as a Distinguished Fellow by ASAM is a profound honor," said Dr. Kirby. "It's a privilege to stand alongside so many esteemed leaders who are transforming the future of addiction medicine." With dual board certifications in addiction medicine and family medicine, and deep expertise in healthcare policy and population health, Dr. Kirby exemplifies the innovative and empathetic leadership PursueCare brings to the field. Visit PursueCare at Booth #325—Experience RESET® and RESET-O® Conference attendees are invited to Booth #325 to experience PursueCare's cutting-edge, virtual-first addiction treatment platform. The company will spotlight its latest advancements, including: RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video Transforming Addiction Treatment with RESET®. Tools that offer 24/7 recovery support, blending cognitive behavioral therapy (CBT), contingency management, and real-time progress tracking within PursueCare's secure, proprietary smartphone applications. These groundbreaking therapeutics are seamlessly embedded into PursueCare's care model, extending the reach and impact of virtual addiction care. Elevating the Standards of Recovery "Dr. Kirby's recognition as a Distinguished Fellow is a proud moment for everyone at PursueCare," said Nick Mercadante, Founder and Chief Executive Officer. "His tireless work to expand access and improve outcomes in virtual addiction treatment reflects our mission to reimagine what recovery looks like for people everywhere." With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, NH, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. Learn more at and View source version on Contacts Media Andreea Popa Head of Sign in to access your portfolio
Business Wire
21-04-2025
- Health
- Business Wire
PursueCare to Spotlight Next-Gen Digital Therapeutics at the 56 th American Society of Addiction Medicine (ASAM) Conference in Denver April 24-27
DENVER--(BUSINESS WIRE)--PursueCare, a leading provider of virtual addiction treatment and specialized pharmacy services, is proud to announce its participation in the 56th Annual American Society of Addiction Medicine (ASAM) Conference in Denver, Colo., April 24-27, 2025. The event gathers top experts, clinicians, and innovators in addiction medicine to advance science, practice, and policy in the field. With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions. Share Honoring a Visionary in Addiction Medicine—Dr. Jason Kirby Named 2025 ASAM Distinguished Fellow PursueCare's Medical Director, Dr. Jason Kirby, DO, MBA, DFASAM, has been named a 2025 Distinguished Fellow of ASAM, one of the society's highest honors. This prestigious designation recognizes Dr. Kirby's enduring commitment to evidence-based, outcomes-driven care and his leadership in improving access to treatment for individuals with substance use disorder (SUD). 'I began this journey nearly a decade ago with a mission to provide compassionate, science-backed care for people living with addiction. Being recognized as a Distinguished Fellow by ASAM is a profound honor,' said Dr. Kirby. 'It's a privilege to stand alongside so many esteemed leaders who are transforming the future of addiction medicine.' With dual board certifications in addiction medicine and family medicine, and deep expertise in healthcare policy and population health, Dr. Kirby exemplifies the innovative and empathetic leadership PursueCare brings to the field. Visit PursueCare at Booth #325—Experience RESET® and RESET-O® Conference attendees are invited to Booth #325 to experience PursueCare's cutting-edge, virtual-first addiction treatment platform. The company will spotlight its latest advancements, including: RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video Transforming Addiction Treatment with RESET®. Tools that offer 24/7 recovery support, blending cognitive behavioral therapy (CBT), contingency management, and real-time progress tracking within PursueCare's secure, proprietary smartphone applications. These groundbreaking therapeutics are seamlessly embedded into PursueCare's care model, extending the reach and impact of virtual addiction care. Elevating the Standards of Recovery 'Dr. Kirby's recognition as a Distinguished Fellow is a proud moment for everyone at PursueCare,' said Nick Mercadante, Founder and Chief Executive Officer. 'His tireless work to expand access and improve outcomes in virtual addiction treatment reflects our mission to reimagine what recovery looks like for people everywhere.' With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, NH, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. Learn more at and
